Physical activity assessment tools for use in overweight and obese children.

The prevalence of excess weight in children and adults worldwide has increased rapidly in the last 25 years. Obesity is positively associated with increased risk for many health issues such as type 2 diabetes, cardiovascular disease and psychosocial problems. This review focuses on child populations, as it is known that the sedentary behaviors of overweight/obese youth often endure into adulthood. Assessment of physical activity (PA), among other factors such as diet and socio-economic status, is important in understanding weight variation and in designing interventions. This review highlights common subjective and objective PA assessment tools, the validity of these methods and acceptable ways of collecting and interpreting PA data. The aim is to provide an update on PA assessment in overweight/obese children, highlighting current knowledge and any gaps in the literature, in order to facilitate the use of PA assessments and interventions by health-care professionals as well as suggest future research in this area.

Performance of entropy and Bispectral Index as measures of anaesthesia effect in children of different ages.

BACKGROUND: Entropy and Bispectral Index (BIS) have been promoted as EEG-based anaesthesia depth monitors. The EEG changes with brain maturation, but there are limited published data describing the characteristics of entropy in children, and some data suggest that BIS is less reliable in young children. The aim of this study was to compare the performance of entropy as a measure of anaesthetic effect in different age groups. The performance of entropy was compared with BIS. METHODS: Fifty-four children receiving a standard sevoflurane anaesthetic for cardiac catheter studies were enrolled. The entropy and BIS were recorded pre-awakening and at 1.5%, 2% and 2.5% steady-state end-tidal sevoflurane concentrations. For analysis children were divided into four age groups: 0-1 yr, 1-2 yr, 2-4 yr and 4-12 yr. RESULTS: The pre-awakening values were obtained in 46 children. The median pre-awakening values for entropy and BIS varied significantly across ages with the values being lowest in the 0-1 yr age group (response entropy: 45 vs 84, 87 and 89, P=0.003; state entropy: 36 vs 78, 74 and 77, P=0.009; BIS: 56 vs 78, 76.5 and 72, P=0.02). Values were recorded at all three sevoflurane concentrations in 48 children. Compared with older groups, the 0-1 yr age group had the least significant difference in BIS and entropy when compared among different sevoflurane concentrations. The calculated sevoflurane concentrations to achieve mid-scale values of entropy and BIS were highest in the 1-2 yr age group, lower in the 0-1 yr age group and progressively lower in the 2-4 and 4-12 yr age groups. CONCLUSIONS: For both entropy and BIS the measure of anaesthetic effect was significantly different for children aged <1 yr compared with older children. There was no difference in performance of entropy and BIS. Both should be used cautiously in small children.

Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury.

This study investigated whether aldose reductase (AR) inhibition with zopolrestat, either alone or in combination with an adenosine A(3)-receptor agonist (CB-MECA), reduced myocardial ischemic injury in rabbit hearts subjected to 30 min of regional ischemia and 120 min of reperfusion. Zopolrestat reduced infarct size by up to 61%, both in vitro (2 nM to 1 microM; EC(50) = 24 nM) and in vivo (50 mg/kg). Zopolrestat reduced myocardial sorbitol concentration (index of AR activity) by >50% (control, 15.0 +/- 2.2 nmol/g; 200 nM zopolrestat, 6.7 +/- 1.3 nmol/g). A modestly cardioprotective concentration of CB-MECA (0.2 nM) allowed a 50-fold reduction in zopolrestat concentration while providing a similar reduction in infarct size (infarct area/area at risk: control, 62 +/- 2%; 1 microM zopolrestat, 24 +/- 5%; 20 nM zopolrestat plus 0.2 nM CB-MECA, 20 +/- 4%). In conclusion, AR inhibition is cardioprotective both in vitro and in vivo. Furthermore, combining zopolrestat with an A(3) agonist allows a reduction in the zopolrestat concentration while maintaining an equivalent degree of cardioprotection.

A case-control study of breast cancer in relation to the use of steroid contraceptive agents.

In a case-control study of 141 cases of breast cancer and 279 control patients from the Royal Prince Alfred and Westmead Hospitals during 1980-1982, we found similar risk factors to those reported for other populations. There was no statistically significant evidence of an increased risk of cancer from the use of oral contraceptive agents; the crude estimate of relative risk for patients who had used oral contraceptive agents at some time was 1.3 with 95% confidence limits of 0.8 and 1.9. After adjustment for other risk factors (age at first live birth, age at menarche, number of pregnancies, menopausal status, bilateral oophorectomy and years of education), the estimate of the relative risk of ever having used an oral contraceptive agent was 0.9 with 95% confidence limits of 0.6 and 1.5. Further analysis in terms of duration of use and dosage also provided no evidence of an increased risk.